MRK

The company's history begins with a transatlantic split. The original Merck was founded in Germany in the seventeenth century and entered the United States through an arm established in 1891 by Georg Merck. During the First World War the United States seized the American subsidiary as enemy property, and in 1917 it was confiscated and set on a path to independence. George W. Merck, the founder's American descendant, helped build the separated company into a domestic pharmaceutical power, while the German parent continued on its own as what is today Merck KGaA. The two have been entirely separate companies for more than a century, which is why the naming convention exists. Across the twentieth century the American Merck grew through internal discovery and acquisition, producing a long line of important medicines in cholesterol, hypertension, and infectious disease, and it merged with Schering-Plough in 2009 in a deal that significantly broadened its reach. In 2021 it sharpened its focus by spinning off Organon, a separate publicly traded company that took the women's health, biosimilars, and established off-patent products, leaving Merck concentrated on innovative branded drugs, vaccines, and animal health.

The business today is organized around three broad areas. The largest by far is human health pharmaceuticals, which spans oncology, vaccines, cardiovascular and pulmonary disease, immunology, infectious disease, and other therapeutic categories. Within human health the company drew an organizational line in early 2026, splitting the division into a dedicated Oncology unit and a separate Specialty, Pharma and Infectious Diseases unit, a deliberate move to give the non-cancer assets the same commercial intensity that Keytruda has long enjoyed. The second area is Animal Health, a business that sells vaccines and medicines for livestock and companion animals and that generated roughly six billion dollars in annual sales as of 2025, growing steadily and diversifying the company away from its dependence on human pharmaceuticals. The third area is the vaccine franchise, which sits inside human health but functions as a distinct engine, led by the Gardasil family and a growing set of pneumococcal products including Vaxneuvance and the newer Capvaxive.

The economic engine, and the reason for the company's durability, is Keytruda. The drug is a checkpoint inhibitor, a type of immunotherapy that releases a brake the immune system places on itself so that the body's own T cells can attack tumors. Keytruda has been approved in dozens of cancer types and lines of treatment, an unusually broad label that took years and an enormous volume of clinical trials to assemble, and that breadth is itself a moat because no biosimilar competitor can instantly match every approved use. By the mid 2020s Keytruda was generating around thirty billion dollars a year, more revenue than any single medicine in the history of the industry, and it carried high margins because the development cost was already sunk. That concentration is a strength while the patents hold and a vulnerability the moment they do not. The broader pharmaceutical moat is familiar. Bringing a new drug from discovery through trials and regulatory approval costs well over a billion dollars and takes many years, which protects incumbents with deep pipelines and discourages thinly funded challengers, and Merck reinvests heavily into research and business development to keep replacing the revenue that patents eventually erase.

That replacement problem is now the defining strategic challenge. Keytruda's core composition-of-matter patent in the United States is expected to expire in 2028, exposing more than twenty five billion dollars of annual revenue to biosimilar competition. Chief Executive Robert Davis has described the event as more of a hill than a cliff, arguing that the decline will be managed rather than sudden, and the company has built several defenses. The most direct is a subcutaneous version of the drug, marketed under the Keytruda Qlex name, which is injected under the skin in minutes rather than infused intravenously over a longer hospital visit. By converting patients to the subcutaneous formulation before biosimilars of the intravenous version arrive, Merck aims to retain a meaningful share of the franchise, since the new formulation carries its own patent protection and offers genuine convenience to patients and clinics. The strategy is sometimes called a product hop, and how much of the franchise it preserves will shape the company's trajectory through the end of the decade.

Beyond the Keytruda defense, Merck is spending aggressively to build the next generation of products. It struck a large collaboration with Daiichi Sankyo to co-develop a set of antibody drug conjugates, a class of cancer therapy that links a targeting antibody to a potent toxin, in a deal whose upfront and contingent payments could reach into the tens of billions of dollars. It acquired Verona Pharma in 2025 for roughly ten billion dollars, adding Ohtuvayre, the first novel inhaled mechanism for chronic obstructive pulmonary disease in more than two decades, to a growing cardio-pulmonary portfolio. Internally developed assets are also scaling. Winrevair, a treatment for pulmonary arterial hypertension acquired through the earlier purchase of Acceleron, moved quickly from launch toward blockbuster scale, and Welireg addresses certain kidney cancers and von Hippel-Lindau disease. The company has also been advancing an oral medicine for high cholesterol and other cardiometabolic and immunology candidates, all part of an effort to assemble enough new revenue to offset the Keytruda decline.

Competition is intense across every front. In immuno-oncology, Merck's Keytruda competes most directly with Bristol Myers Squibb's Opdivo, and the entire checkpoint inhibitor field faces a coming wave of biosimilars. In the broader pharmaceutical race, Merck contends with the largest global drugmakers, including Pfizer, Johnson & Johnson, Roche, AstraZeneca, Novartis, and an ascendant Eli Lilly whose metabolic franchise has reshaped industry economics. In vaccines, the company faces competition and also genuine demand volatility, illustrated by a sharp decline in Gardasil sales driven largely by weaker demand in China, a reminder that even a dominant vaccine depends on specific markets and public health dynamics. In Animal Health, the chief rivals are Zoetis and Boehringer Ingelheim. Across all of these, scale in manufacturing, regulatory expertise, and the sheer cost of clinical development favor the established players, but no incumbent is insulated from a competitor's breakthrough or a key product's patent loss.

Leadership reflects the moment. Robert Davis became chief executive in 2021 after serving as chief financial officer, and he added the chairman title in 2022, an unusual path that gives the company a leader fluent in both capital allocation and operations at a time when deal making and disciplined spending matter enormously. His tenure has been defined by the pivot away from a single-drug narrative toward a diversified portfolio, the Organon spin-off that preceded him, and the organizational split that separated oncology from the rest of human health. The strategy is straightforward to state and hard to execute. Use the cash that Keytruda still generates to fund internal research and to acquire external assets, broaden the revenue base so that no future product is as singularly important as Keytruda has been, and manage the patent transition so the decline is gradual rather than abrupt. The company has the balance sheet to pursue acquisitions and the research infrastructure to develop candidates internally, and it pays a substantial dividend that anchors it as a relatively defensive holding within healthcare.

The risks are specific and well understood. The largest is concentration. A single drug accounting for a large share of revenue means the 2028 patent expiry is an event of unusual magnitude, and if the subcutaneous conversion and the new pipeline underdeliver, the revenue gap could be severe. Drug development itself is uncertain, and the company has already seen setbacks, including a withdrawn application within the Daiichi Sankyo antibody drug conjugate program, a reminder that expensive bets do not always pay off. Acquisitions carry integration and valuation risk, and paying tens of billions for external assets raises the cost of being wrong. Pricing pressure is a structural headwind across the industry, with United States drug pricing reform and government negotiation of certain medicines threatening margins on established products. Vaccine demand can swing on geography and policy, as the China driven Gardasil decline showed. And regulatory, legal, and manufacturing risks are constant features of a business that makes complex biologics at global scale.

For an investor, Merck presents a clear and unusually well-defined trade-off. The company owns one of the most valuable franchises pharmaceutical history has produced, generates substantial cash, and reinvests it into a deep pipeline and a steady stream of acquisitions, all under a management team that has been candid about the challenge ahead. Set against that is the single largest patent expiry any drugmaker has ever faced, arriving on a known timeline near the end of the decade. The forward question is not whether Keytruda will eventually lose exclusivity, since it will, but how much of its revenue Merck can defend through the subcutaneous transition and how successfully the company can manufacture a new generation of large products from its pipeline and dealmaking before the decline takes hold. The widget above tracks the live financial picture as that transition unfolds.